GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10/11/2026
Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 Major BLA amendment added two-year open-label extension (OLE) HOPE-3 [...]
Bionano Reports Third Quarter 2026 Results and Provides a Business Update
10/11/2026
Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026 [...]
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
10/11/2026
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for [...]
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
10/11/2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
10/11/2026
Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in [...]
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
10/11/2026
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, [...]
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
10/11/2026
A majority-owned and controlled subsidiary of Fortress entered into an agreement with Cedars-Sinai to license FB-607, which is currently being evaluated in an ongoing Phase 2 study for IBS-D MIAMI, Nov. 10, 2026 (GLOBE [...]
Glass House Brands to Host Third Quarter 2026 Earnings Call on November 16, 2026
10/11/2026
LONG BEACH, Calif. and TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis companies in the U.S., [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
10/11/2026
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the [...]
Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance
10/11/2026
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for [...]
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
10/11/2026
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM [...]
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
10/11/2026
Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander Annamycin achieves substantially [...]
Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology
10/11/2026
Latest patent expands intellectual property protection for advanced physiological signal acquisition and processing THE WOODLANDS, TX, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix [...]
Bon Secours Mercy Health names Shon Baker foundation president, chief philanthropy officer
10/11/2026
Veteran philanthropy executive will strengthen donor partnerships to advance the ministry’s mission, extend its impact and support continued growth CINCINNATI, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CINCINNATI, Ohio (Nov. 10 [...]
Inviah Healthcare Technology Platform Moves from Beta to Full Launch in Illinois to Bring Doctors and Quality Healthcare Directly to Patients’ Homes
10/11/2026
Physician-led healthcare company connects patients through the Inviah mobile app with credentialed doctors on demand, making medical care more accessible and convenient CHICAGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inviah [...]
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
10/11/2026
At Week 16, 69% of participants receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin, with at least a 2-category improvement, compared with 0% receiving placebo Improvements in skin disease activity were [...]
Pain clinics in Ontario call for transparency amid concerns over future treatment access
10/11/2026
Save Pain Clinics seeks answers on potential changes to OHIP-funded nerve blocks and interventional pain injections for chronic pain TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Patients and clinicians across Ontario are [...]
Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
10/11/2026
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings 1 Nearly two-thirds of patients on continuous ianalumab reached low disease activity at [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2026
10/11/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum